admin – Page 4560 – Get News Story

Dubai Weeklys Unveils Highlights of Winter City Expo 2024 and New Year’s Eve 2025

Dubai, renowned for its innovation and grandeur, is set to host the Winter City Expo from December 6 to December 31, 2024, at Expo City Dubai.

This annual event transforms the city into a winter wonderland, offering a blend of cultural festivities, technological showcases, and family-friendly entertainment.

Event Highlights

Dates and Timings: The Expo runs daily from 2:00 PM to 10:00 PM, providing ample opportunity for visitors to immerse themselves in the festive spirit.
Venue: Expo City Dubai, a state-of-the-art location that previously hosted Expo 2020, serves as the backdrop for this festive celebration.
Winter Wonderland Experience: Visitors can enjoy artificial snow, ice sculptures, and interactive snow-themed activities, creating an authentic winter atmosphere in the heart of the desert.
Festive Markets: The Expo features Christmas markets offering a variety of handcrafted goods, festive foods, and unique souvenirs, perfect for holiday shopping.
Live Performances: Attendees can look forward to carol performances, theatrical shows, and musical acts that add to the festive ambiance.
Family-Friendly Activities: With dedicated zones for children, the Expo offers workshops, games, and entertainment suitable for all ages.
Pricing: Entry fees start at AED 40 online, with various packages available to enhance the visitor experience.
Purchase Options: Tickets can be purchased online through official platforms, ensuring a seamless entry process.

Attractions and Activities Ticket Information

New Year’s Eve 2025 in Dubai: A Spectacular Celebration

As the year draws to a close, Dubai prepares to host some of the most extravagant New Year’s Eve celebrations worldwide. Here’s what to expect as you welcome 2025 in this vibrant city.

Iconic Fireworks Displays

Burj Khalifa: The world’s tallest building is renowned for its breathtaking fireworks and light shows, attracting spectators globally.
Atlantis The Palm: This luxury resort hosts a grand fireworks display, often accompanied by live performances and gala dinners.
The Pointe at Palm Jumeirah: Offering a waterfront view, The Pointe provides a stunning backdrop for fireworks, complemented by dining and entertainment options.
Gala Dinners: Many of Dubai’s luxury hotels and restaurants offer exclusive New Year’s Eve gala dinners, featuring gourmet cuisine, live entertainment, and views of the city’s fireworks.
Beach Clubs and Yacht Parties: For those seeking a lively atmosphere, beach clubs and yacht parties provide music, dancing, and a festive environment to ring in the new year.
Global Village: This multicultural festival park offers family-friendly New Year’s Eve celebrations, including fireworks and cultural performances.
Dubai Festival City Mall: Known for its impressive IMAGINE laser and fountain shows, the mall provides a family-oriented environment to celebrate the new year.
Accommodation: Given the influx of tourists during the festive season, it’s advisable to book accommodations well in advance.
Transportation: Dubai’s public transport operates extended hours during New Year’s Eve, but due to high demand, consider arranging private transportation or arriving early at your chosen venue.
Dress Code: While Dubai is relatively liberal, it’s recommended to adhere to a smart-casual dress code, especially when attending upscale events.
Crowd Management: Authorities implement crowd control measures to ensure public safety during large gatherings, particularly around popular areas like Downtown Dubai.
Health Precautions: Stay informed about any health advisories or requirements, such as mask mandates or vaccination proof, that may be in place during your visit.

Exclusive Events and Parties Family-Friendly Celebrations Planning Your Visit Safety Measures Conclusion

Dubai’s Winter City Expo 2024 and New Year’s Eve in Dubai 2025 celebrations offer a unique blend of cultural experiences, entertainment, and luxury. Whether you’re exploring the winter-themed attractions at the Expo or witnessing the city’s iconic fireworks displays, Dubai provides an unforgettable setting to conclude the year and usher in new beginnings.

Follow Dubai weeklys to explore more about Dubai

Media Contact
Company Name: Dubai Weeklys
Contact Person: Andrew Jackson
Email: Send Email
City: Dubai
Country: United Arab Emirates
Website: https://dubaiweeklys.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dubai Weeklys Unveils Highlights of Winter City Expo 2024 and New Year’s Eve 2025

Surgical Site Infections Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

DelveInsight’s “Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Discover Key Insights into the Surgical Site Infections Market with DelveInsight’s In-Depth Report @ Surgical Site Infections Market Size

Key Takeaways from the Surgical Site Infections Market Report

The Surgical Site Infections market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
According to findings, surgical site infection occur in 2% to 4% of all patients undergoing inpatient surgical procedures.
Findings show that the overall incidence of surgical site infections was approximately 10% in the early 2000s, decreased to 7% by 2007, and further declined to 5% by 2020.
The leading Surgical Site Infections Companies such as MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others
Promising Surgical Site Infections Therapies such as Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others

Navigate the complexities of the Surgical Site Infections Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Surgical Site Infections Market Forecast. Click here to get more insights @ Surgical Site Infections Treatment Market

Surgical Site Infections Epidemiology Segmentation in the 7MM

Total Prevalence of Surgical Site Infections
Prevalent Cases of Surgical Site Infections by severity
Gender-specific Prevalence of Surgical Site Infections
Diagnosed Cases of Episodic and Chronic Surgical Site Infections

Download the report to understand which factors are driving Surgical Site Infections epidemiology trends @ Surgical Site Infections Prevalence

Surgical Site Infections Emerging Drugs

D-PLEX100: PolyPid

D-PLEX is a new formulation of extended release of Doxycycline. D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable. The company is conducting a Phase III, prospective, multinational, multicenter, randomized, controlled, two-arm, double blind study to assess efficacy and safety of D-PLEX administered concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incisional infection.

XF-73 Nasal gel: Destiny Pharma

XF-73 Nasal gel, a dicationic porphyrin derivative, possesses strong bactericidal properties through a unique mechanism of action. It is a newly developed compound aimed at preventing Staphylococcal infections following surgical procedures. XF-73 Nasal gel is fast acting, requires very few applications and it has a very low propensity to develop bacterial resistance. Thus, XF-73 Nasal gel, preventing post-surgical infections, has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. In April 2024, Destiny Pharma disclosed audited results for 2023, announcing a strategic review to advance XF-73 nasal through Phase III trials. They also re-evaluated trial costs, developing a cost-effective design, and enhanced market understanding for partnerships.

Surgical Site Infection Market Outlook

The market for surgical site infection treatments is anticipated to grow significantly, driven by key players like PolyPid and Destiny Pharma, who are advancing their lead candidates through various clinical stages. PolyPid’s D-PLEX100 and Destiny Pharma’s XF-73, among other innovative therapies, aim to provide targeted and effective solutions for preventing and treating surgical site infection. The rising prevalence of surgical site infection, the increasing number of surgical procedures, and enhanced diagnostic technologies underscore the urgent need for advanced treatments.

Get In-Depth Knowledge on Surgical Site Infections Market Trends and Forecasts with DelveInsight @ Surgical Site Infections Treatment Market

Surgical Site Infections Therapies and Companies

Ciprodiazole: MinaPharm Pharmaceuticals
DFA-02 Antibiotic Gel: Duke Clinical Research Institute
ZuraPrep: Zurex Pharma, Inc.
Ertapenem: Merck Sharp & Dohme LLC
XF-73: Destiny Pharma Plc
D-PLEX: PolyPid Ltd.
cefuroxime: GlaxoSmithKline
Dalbavancin: Durata Therapeutics
daptomycin: Cubist Pharmaceutical
ZuraGard: Zurex Pharma, Inc.

Surgical Site Infections Treatment Market

Treatment for surgical site infections (SSIs) typically involves antibiotics tailored to the specific pathogens identified through wound cultures. The choice of antibiotics is crucial for effectively targeting the infection and reducing resistance. In some cases, if the infection does not respond to antibiotic therapy or if it involves deeper tissues or foreign materials, additional surgical intervention may be required to remove infected tissue, drain abscesses, or address complications. Prompt and appropriate management is essential to prevent the spread of infection, reduce recovery time, and minimize the risk of long-term complications.

Gain a strategic edge in the Surgical Site Infections Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Surgical Site Infections Market Forecast. Click here to lead in advancements @ Surgical Site Infections Clinical Trials Assessment

Scope of the Surgical Site Infections Market Report

Study Period: 2020-2034
Coverage: 7MM
Surgical Site Infections Companies: MinaPharm Pharmaceuticals, Duke Clinical Research Institute, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., GlaxoSmithKline, Durata Therapeutics, Cubist Pharmaceutical, Zurex Pharma, Inc., and others
Surgical Site Infections Therapies: Ciprodiazole, DFA-02 Antibiotic Gel, ZuraPrep, Ertapenem, XF-73, D-PLEX, cefuroxime, Dalbavancin, daptomycin, ZuraGard, and others
Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies
Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Surgical Site Infections Unmet Needs, KOL’s views, Analyst’s views, Surgical Site Infections Market Access and Reimbursement

Table of Contents

1. Surgical Site Infections Market Report Introduction

2. Executive Summary for Surgical Site Infections

3. SWOT analysis of Surgical Site Infections

4. Surgical Site Infections Patient Share (%) Overview at a Glance

5. Surgical Site Infections Market Overview at a Glance

6. Surgical Site Infections Disease Background and Overview

7. Surgical Site Infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Surgical Site Infections

9. Surgical Site Infections Current Treatment and Medical Practices

10. Surgical Site Infections Unmet Needs

11. Surgical Site Infections Emerging Therapies

12. Surgical Site Infections Market Outlook

13. Country-Wise Surgical Site Infections Market Analysis (2020-2034)

14. Surgical Site Infections Market Access and Reimbursement of Therapies

15. Surgical Site Infections Market Drivers

16. Surgical Site Infections Market Barriers

17. Surgical Site Infections Appendix

18. Surgical Site Infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Surgical Site Infections Therapeutics Market Size in the 7MM is expected to increase by 2034, estimates DelveInsight

Knee Osteoarthritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies Involved by DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Knee Osteoarthritis pipeline constitutes 50+ key companies continuously working towards developing 60+ Knee Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Knee Osteoarthritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market.

Some of the key takeaways from the Knee Osteoarthritis Pipeline Report:

Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years.
Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Knee Osteoarthritis treatment

Emerging Knee Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.
In September 2024, Cytonics has announced the completion of subject enrollment for its Phase I clinical trial of CYT-108, a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor. The company initiated this Phase I trial in July, which is a first-in-human, multicenter, six-month, double-blind, randomized controlled trial (RCT) aimed at evaluating the safety and efficacy of CYT-108 in patients with unilateral, mild-to-moderate primary OA of the knee.
In June 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage company focused on macrophage reprogramming immunotherapy, announced a positive interim data update from a Phase I/II investigator-initiated clinical trial of Allocetra™ in patients with end-stage knee osteoarthritis who were candidates for knee replacement surgery.

Knee Osteoarthritis Overview

Knee osteoarthritis is a degenerative joint disease that occurs when the protective cartilage in the knee joint wears down over time. This leads to pain, stiffness, swelling, and reduced mobility. The condition is most common in older adults but can also affect younger individuals due to injury or genetic factors. Risk factors include age, obesity, previous knee injuries, and family history. Symptoms often worsen with activity and improve with rest. Treatment options include physical therapy, pain management with medications, lifestyle changes like weight loss, and in severe cases, surgical interventions such as knee replacement.

Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight

Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include:

M6495: Merck KGaA
PPV 06: Peptinov
LG00034053: LG Chem
StroMel: Akan Bioscience
TTAX03: BioTissue,Inc.
EP-104IAR: Eupraxia Pharmaceuticals Inc.
OLP 1002: OliPass Corporation
JTA-004: Bone Therapeutics
X 0002: Techfields Pharma
Lorecivivint: Biosplice Therapeutics

Knee Osteoarthritis Route of Administration

Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Knee Osteoarthritis Molecule Type

Knee Osteoarthritis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Knee Osteoarthritis Pipeline Therapeutics Assessment

Knee Osteoarthritis Assessment by Product Type
Knee Osteoarthritis By Stage and Product Type
Knee Osteoarthritis Assessment by Route of Administration
Knee Osteoarthritis By Stage and Route of Administration
Knee Osteoarthritis Assessment by Molecule Type
Knee Osteoarthritis by Stage and Molecule Type

DelveInsight’s Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies

Some of the key companies in the Knee Osteoarthritis Therapeutics Market include:

Key companies developing therapies for Knee Osteoarthritis are – Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others.

Knee Osteoarthritis Pipeline Analysis:

The Knee Osteoarthritis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies

Knee Osteoarthritis Pipeline Market Drivers

Increase in prevalence of Osteoarthritis, robust Knee Osteoarthritis Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market.

Knee Osteoarthritis Pipeline Market Barriers

However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth.

Scope of Knee Osteoarthritis Pipeline Drug Insight

Coverage: Global
Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others
Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others
Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers

Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials

Table of Contents

1. Knee Osteoarthritis Report Introduction

2. Knee Osteoarthritis Executive Summary

3. Knee Osteoarthritis Overview

4. Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment

5. Knee Osteoarthritis Pipeline Therapeutics

6. Knee Osteoarthritis Late Stage Products (Phase II/III)

7. Knee Osteoarthritis Mid Stage Products (Phase II)

8. Knee Osteoarthritis Early Stage Products (Phase I)

9. Knee Osteoarthritis Preclinical Stage Products

10. Knee Osteoarthritis Therapeutics Assessment

11. Knee Osteoarthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Knee Osteoarthritis Key Companies

14. Knee Osteoarthritis Key Products

15. Knee Osteoarthritis Unmet Needs

16 . Knee Osteoarthritis Market Drivers and Barriers

17. Knee Osteoarthritis Future Perspectives and Conclusion

18. Knee Osteoarthritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Knee Osteoarthritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies Involved by DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia

Pain Clinic In Denver Proudly Offered by Denver Pain Management Clinic

Denver Pain Management Clinic, a leading provider of chronic pain management services, has expanded its offerings to serve as a comprehensive pain clinic in Denver.

Denver Pain Management Clinic, a leading provider of chronic pain management services, has expanded its offerings to serve as a comprehensive pain clinic in Denver. This development brings advanced pain management solutions to the local community, addressing the growing need for effective and personalized chronic pain treatment.

The pain clinic in Denver offers a range of services designed to help individuals manage chronic pain and improve their quality of life. Utilizing a combination of medical expertise, cutting-edge technology, and personalized care, Denver Pain Management Clinic aims to provide tailored solutions for those struggling with various pain conditions.

Dr. Andrew Hong, spokesperson for Denver Pain Management Clinic, commented on the clinic’s approach: “At Denver Pain Management Clinic, we understand that chronic pain is a complex issue that requires a multifaceted approach. Our team works closely with patients to develop effective and individualized treatment plans that not only decrease pain but also improve function and overall quality of life.”

The clinic’s focus on comprehensive pain management sets it apart from traditional pain treatment centers. By providing a wide range of services, including physical therapy, neuromodulation, and treatment for complex conditions such as Complex Regional Pain Syndrome (CRPS), Denver Pain Management Clinic ensures that patients receive well-rounded care tailored to their specific needs.

As a specialist serving Denver, CO, Dr. Hong brings a wealth of experience and expertise to the clinic. Having completed both his Bachelor of Science and Doctorate of Medicine at the University of Wisconsin-Madison, followed by a residency at the University of Colorado, Dr. Hong is well-equipped to handle a variety of pain conditions. His recognition as a member of the Colorado Pain Society and the American Academy of Pain Medicine further underscores his commitment to providing high-quality pain care.

The clinic’s approach to pain management goes beyond just treating physical symptoms. Recognizing that chronic pain can often lead to stress, anxiety, and depression, Denver Pain Management Clinic takes a holistic approach to patient care. This comprehensive strategy addresses both the physical and emotional aspects of chronic pain, helping patients improve their overall well-being.

As a chronic pain and wellness center, Denver Pain Management Clinic utilizes an assortment of narcotic and non-narcotic analgesic medications to block pain and provide comfort. However, their treatment options extend far beyond medication. The clinic also incorporates advanced technologies and techniques, such as neuromodulation, to offer patients cutting-edge pain management solutions.

The clinic’s expertise in treating movement disorders further expands its capacity to help patients with complex pain conditions. By addressing the intricate relationship between pain and movement, Denver Pain Management Clinic provides more comprehensive care for patients dealing with conditions that affect both pain perception and mobility.

Colorado pain care Denver has seen significant advancements with the expansion of Denver Pain Management Clinic’s services. The clinic’s commitment to staying at the forefront of pain management techniques ensures that patients have access to the most current and effective treatments available.

Dr. Hong emphasized the importance of individualized care: “Every patient’s experience with pain is unique. That’s why we take the time to thoroughly assess each patient’s condition and develop a personalized treatment plan. Our goal is not just to manage pain, but to improve our patients’ overall quality of life and help them regain function.”

The clinic’s focus on patient education and empowerment is another key aspect of their approach. By helping patients understand their conditions and treatment options, Denver Pain Management Clinic enables individuals to take an active role in their pain management journey.

Since its establishment in 2010, Denver Pain Management Clinic has been proudly serving the community, building a reputation as a trusted pain and wellness center. Their expansion of services reflects their ongoing commitment to meeting the evolving needs of patients dealing with chronic pain in the Denver area.

For more information please contact Dr. Andrew Hong at +17204052330.

About Denver Pain Management Clinic:

Denver Pain Management Clinic is a leading provider of chronic pain management services in Colorado. Established in 2010, the clinic offers comprehensive pain care solutions, including medication management, physical therapy, neuromodulation, and treatment for complex pain conditions. Led by Dr. Andrew Hong, a recognized member of the Colorado Pain Society and the American Academy of Pain Medicine, the clinic is committed to providing personalized, effective pain management strategies to improve patients’ function and quality of life. With a focus on holistic care and cutting-edge treatments, Denver Pain Management Clinic stands at the forefront of pain management in the Denver area.

Media Contact
Company Name: Denver Pain Management Clinic
Contact Person: Dr. Andrew Hong
Email: Send Email
Phone: +17204052330
Address:455 Sherman St # 450
City: Denver
State: CO
Country: United States
Website: https://denverpainmanagementclinic.com/

American Consumer Awards (ACA) Unveils “Sports & Leisure” Category Winners for Texas, Hosted by the American Consumer Right Association (ACRA)

The results of the 2024 American Consumer Awards in the ‘Sports & Leisure’ category, organized by the American Consumer Right Association (ACRA) and managed by the American Consumer Assessment (ACA), have been announced for the Texas region.

These awards aim to uphold consumers’ fundamental rights by sharing results based on consumer evaluations, providing objective and valuable information, and promoting the qualitative enhancement of consumers’ lives.

Evaluations for the 2024 American Consumer Awards ‘Sports & Leisure’ category were conducted from July to October and were based on online reviews from real consumers. The evaluation criteria included staff friendliness, facility satisfaction, pricing satisfaction, accessibility, and service satisfaction. Several outstanding businesses were recognized for their excellence in this category.

The winners are as follows:

Colaw Fitness (S Cooper St)

Skydive Houston

HT Fitness (E. 12421 US-290)

PINSTACK (N Central Expy)

Academy Sports + Outdoors (San Bernardo Ave)

K1 Speed (Mc Hale Ct)

Speedy’s Fast Track

Top Gun Range

Momentum Indoor Climbing Silver Street

AGR Sports Indoor Paintball. Laser Tag. Gellyball and Axe Throwing

Axe Masters Texas

Bike Mart (W Campbell Rd)

Interskate Roller Rink

Skydive Spaceland Dallas

Broadway Powersports

GolfSuites Lubbock

2nd Swing Golf (Hwy 121)

Madddogz Paintball

Shoot Smart: Range. Training. Gunsmith. (N Fwy)

Galleria Ice Skating Center

AGR Sports Adventure Park

LoneStar Handgun

TruFit Athletic Clubs – Park North Center

Bowlero San Antonio

Geronimo Adventure Park

A spokesperson for the American Consumer Right Association stated, “The 2024 American Consumer Awards are grounded in evaluations from real consumers, and we hope these results will provide trustworthy information for consumers and contribute to the growth of the sports and leisure industry. We also believe that these assessments will encourage businesses to prioritize customer satisfaction and continue to offer exceptional service.”

Media Contact
Company Name: American Consumer Right Association
Contact Person: Harvey Reed
Email: Send Email
City: Los Angeles
State: California
Country: United States
Website: https://www.acra-us.org/

Systemic Lupus Erythematosus Therapeutics Market Size in the 7MM was ~USD 3,200 million in 2023, is expected to grow by 2034, and estimates DelveInsight

DelveInsight’s “Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Discover Key Insights into the Systemic Lupus Erythematosus Market with DelveInsight’s In-Depth Report @ Systemic Lupus Erythematosus Market Size

Key Takeaways from the Systemic Lupus Erythematosus Market Research Report

The increase in Systemic Lupus Erythematosus Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
Between EU4 and the UK, Spain accounted for the highest number of diagnosed prevalent cases followed by the UK and Germany.
The age group most affected by the prevalence of systemic lupus erythematosus is 40-59 years. In 2023, among 7MM, approximately 40% of cases belonged to the 40-59 years age group.
In 2023, approximately 50% of cases were found to be moderate cases in Spain..
The leading Systemic Lupus Erythematosus Companies such as GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma/Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, and others.
Promising Systemic Lupus Erythematosus Pipeline Therapies such as LY3471851, Lupuzor, BIIB059, Dapirolizumab pegol, Gazyva, Cenerimod, and others.

Navigate the complexities of the Systemic Lupus Erythematosus Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Systemic Lupus Erythematosus Market Forecast. Click here to get more insights @ Systemic Lupus Erythematosus Treatment Market

Systemic Lupus Erythematosus Epidemiology Segmentation in the 7MM

Total Systemic Lupus Erythematosus Diagnosed Prevalent Cases
Systemic Lupus Erythematosus Age-specific Diagnosed Prevalent Cases
Systemic Lupus Erythematosus Severity-specific Diagnosed Prevalent Cases
Systemic Lupus Erythematosus Gender-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Systemic Lupus Erythematosus epidemiology trends @ Systemic Lupus Erythematosus Prevalence

Systemic Lupus Erythematosus Marketed Drugs

BENLYSTA (belimumab): GlaxoSmithKline

BENLYSTA (belimumab), a B-lymphocyte stimulator (BLyS) specific inhibitor, is a fully human monoclonal antibody that binds to soluble BLyS, which is found to be increased in patients with systemic autoimmune diseases like SLE and lupus nephritis (LN). ABy bding BLyS, BENLYSTA inhibits the prolonged survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. BENLYSTA does not bind B cells directly. The US FDA first approved BENLYSTA for the treatment of active systemic lupus erythematosus; it is the first and only approved biologic for both SLE and LN in more than 50 years, including for the pediatric population. It was first approved by the US FDA in 2011.

SAPHNELO (anifrolumab): AstraZeneca

SAPHNELO (anifrolumab) is a first in class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity. SAPHNELO is approved to treat systemic lupus erythematosus in more than 60 countries worldwide including the US, EU and Japan, with reviews ongoing in other countries.

Systemic Lupus Erythematosus Emerging Drugs Profile

Cenerimod: Idorsia Pharmaceuticals/Viatris

Cenerimod is a highly selective sphingosine-1-phosphate receptor 1 (S1P1) receptor modulator, given as an oral once-daily tablet. While the cause of SLE is not fully known, T and B-lymphocytes are considered the key immune cells playing a role in the development of SLE. T and B-lymphocytes have a cell surface receptor called S1P1. These receptors enable T and B-lymphocytes to detect the signaling molecule S1P – sphingosine 1 phosphate – which is responsible for lymphocyte trafficking from the lymph nodes to the circulation. By binding to S1P1 receptors, a receptor modulator can trigger the internalization of those receptors. This effectively blinds T and B lymphocytes to the S1P gradient, thereby holding them in the lymph nodes and reducing autoreactive T and B cells in the circulation and, consequently, also in the tissues. In December 2017, the US FDA designated the investigation of cenerimod for the treatment of SLE as a fast-track development program. Currently it is in Phase III of its clinical development.

Litifilimab: Biogen

Litifilimab is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of SLE and cutaneous lupus erythematosus (CLE). BDCA2 is a receptor that is predominantly expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs). The binding of litifilimab to BDCA2 has been shown to reduce the production of pro-inflammatory molecules by pDCs, including type-I interferon (IFN-I) as well as other cytokines and chemokines. Currently it is in Phase III of its clinical development.

Get In-Depth Knowledge on Systemic Lupus Erythematosus Market Trends and Forecasts with DelveInsight @ Systemic Lupus Erythematosus Treatment Market

Systemic Lupus Erythematosus Treatment Market

Systemic Lupus Erythematosus treatment include NSAIDs and antimalarial agents, which are the first-line therapies formild SLE. In addition, glucocorticoids and cytotoxic or immunosuppressive agents—such as azathioprine, mycophenolatemofetil, cyclophosphamide, cyclosporine, and methotrexate —are used for SLE with organ involvement. The current market possesses two approved products, Benlysta (belimumab) and Saphnelo (anifrolumab-fnia).

Systemic Lupus Erythematosus Market Dynamics

The Systemic Lupus Erythematosus market dynamics is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. The launch of emerging therapies is expected during the forecast period of 2024–2034. Few major key players of the emerging therapy market of SLE includes GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma/Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, and others

Gain a strategic edge in the Systemic Lupus Erythematosus Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Systemic Lupus Erythematosus Market Forecast. Click here to lead in advancements @ Systemic Lupus Erythematosus Clinical Trials Assessment

Scope of the Systemic Lupus Erythematosus Market Research Report

Coverage- 7MM
Systemic Lupus Erythematosus Companies- GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma/Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, and others.
Systemic Lupus Erythematosus Pipeline Therapies- LY3471851, Lupuzor, BIIB059, Dapirolizumab pegol, Gazyva, Cenerimod, and others.
Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus Market Drivers and Barriers
Systemic Lupus Erythematosus Market Access and Reimbursement, Unmet Needs and Perspectives

Table of Content

1. Key Insights

2. Systemic Lupus Erythematosus Executive Summary

3. Systemic Lupus Erythematosus Competitive Intelligence Analysis

4. Systemic Lupus Erythematosus: Market Overview at a Glance

5. Systemic Lupus Erythematosus: Disease Background and Overview

6. Patient Journey

7. Systemic Lupus Erythematosus Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Systemic Lupus Erythematosus Unmet Needs

10. Key Endpoints of Systemic Lupus Erythematosus Treatment

11. Systemic Lupus Erythematosus Marketed Products

12. Systemic Lupus Erythematosus Emerging Therapies

13. Systemic Lupus Erythematosus: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Systemic Lupus Erythematosus Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Systemic Lupus Erythematosus Market Drivers

19. Systemic Lupus Erythematosus Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Systemic Lupus Erythematosus Therapeutics Market Size in the 7MM was ~USD 3,200 million in 2023, is expected to grow by 2034, and estimates DelveInsight

Instagram Sensation Tora Drums to Release Her Debut Single in 2025

Popular drummer and Instagram sensation Tora Drums has announced the release of her debut single in 2025, sending her fans into a frenzy. Born Khuat Hoa Xuan in Hanoi, Tora Drums is considered a Vietnamese powerhouse who already boasts over 87,000 subscribers on her YouTube channel and has shown technical prowess and undeniable passion for her craft. Her ground-breaking compositions have the potential to completely transform the rhythmic landscape.

Since she started playing the drums in 2017, Tora has been progressively advancing her career. Over the course of her remarkable seven-year journey, the drummer from Hanoi has already put out five original compositions, including instrumentals that highlight her technical prowess and variety.

In her senior year of high school, Tora’s passion for drumming was ignited on the bustling streets of Hanoi, where her narrative began. Tora remembers, “It came very naturally to me.” There weren’t many musicians in my hometown at the time. I fell in love with drums because I wanted to study something artistic.

She soon turned her love of rhythm into a lifetime endeavor. Tora committed herself to endless hours of practice, pushing the limits of her craft despite the lack of resources and opportunities in her village. She eventually created a distinctive style that captivates audiences all around the world by fusing emotional depth with technical accuracy.

Her debut album marks an important turning point in Tora’s career. Although the album’s specifics are being kept under wraps, fans can anticipate a selection of songs that combine her distinctive drumming with avant-garde compositions. The CD attempts to highlight Tora’s diversity and reinterpret what drumming may be in modern music, ranging from soulful rhythms to high-energy beats.

Through her YouTube channel, Tora Drums, which has over 87,000 subscribers, and Instagram account, @toradrums, Tora has established a robust online community. Fans may observe her creative process, take in captivating performances, and establish a personal connection with her journey through her platforms.

Her videos, which feature everything from drum covers to original songs, have won accolades for their inventiveness and technical mastery. Beyond the screen, Tora has worked with other musicians, which has strengthened her standing as a creative and adaptable performer.

Tora’s debut album release is only the first step. She intends to tour with her songs, perform live at locations throughout Vietnam and abroad, and release the album. Along with her own identity as a musician, fans can anticipate new original songs, artist collaborations, and interesting brand partnerships.

According to Tora, “I want to continue developing as an artist and use my music to reach more people.” “This album is only the beginning of what I want to accomplish.”

For the latest updates, follow Tora Drums on Social Media.

Instagram: https://www.instagram.com/toradrums

YouTube: https://www.youtube.com/@toradrum

Media Contact
Company Name: Pro Entertainment Solutions
Contact Person: Media Relations
Email: Send Email
State: New Jersey
Country: United States
Website: www.proentsol.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Instagram Sensation Tora Drums to Release Her Debut Single in 2025

American Consumer Awards (ACA) Unveils “Sports & Leisure” Category Winners for New York, Hosted by the American Consumer Right Association (ACRA)

The winners are as follows:

Bury the Hatchet Axe Throwing Brooklyn

Sky Zone Trampoline Park (Lecount Pl)

Bowlero Times Square

REI (Lafayette St)

Movement LIC

Rab’s Country Lanes

iFLY Indoor Skydiving – Westchester

Bowlero Chelsea Piers

Bowlero White Plains

RPM Raceway | Race Play More (Daniel St)

Sky Zone Trampoline Park (N Jensen Rd)

The North Face Woodbury Common Premium Outlets

Hot Yoga Chelsea / Flatiron NYC

Area53 – Indoor Paintball

Syracuse Bicycle

LA Fitness (Park Ave)

NYRR RUNCENTER featuring the New Balance Run Hub

American Consumer Awards (ACA) Unveils “Sports & Leisure” Category Winners for California, Hosted by the American Consumer Right Association (ACRA)

The winners are as follows:

The Escape Game San Francisco (Downtown)

GoJump Oceanside.

Oceano Dunes State Vehicular Recreation Area

Hansen Dam Aquatic Center

Pins N Pockets

Skydive Perris

Total Body Experts + Studio-Cycles

SC Village

Indian Wells Tennis Garden

K1 Speed (Ontario Mills Pkwy)

Tahoe Sport Fishing

REI (Copley Dr)

Sharks Ice at San Jose

Silicon Valley Skydiving

San Diego Surf School | San Diego Surf Lessons

The Escape Game San Diego

QUEST ROOM – Hollywood Escape Rooms

Seaforth Sportfishing

K1 Speed (District Pl)

Quarry Park Adventures

Gold’s Gym Venice

In-Shape Family Fitness (Valley Center Dr)

Fitness 19 (N Grand Ave)

Concourse Bowling Center

Canyon Bicycles USA

Legion American Jiu Jitsu San Diego – HQ

Road Runner Sports (Newport Blvd)

Flight Adventure Park Bakersfield

Sports Basement Campbell

Up-and-Coming Romance Author Brings Mafia World to Life

“Louise has done a great job making this book the best it could be,” Halday said. “Now, it will delight mafia romance readers and thrill seekers throughout the United States.”

The press release is about the first novel of Alem Halday. It should appeal to mafia romance readers and thriller readers. The author plans a series of romance novels, Romanov Brothers. Book critics and reviewers would be good landing spots for this release.

Alem Halday has hit the Christmas buying season by rereleasing her novel, Shadowed Desire, the first in the Romanov Brothers Series this month. In addition, the week leading up to Christmas, she plans a special to highlight her book. In her first romance novel, Halday brings the reader into the world of organized crime. Alexei Romanov is one of three brothers who run the organization. He is not looking for love, but he meets Natalia, who is from a rival organization. She intrigues him, and he pursues her. The story takes off from there and keeps the readers engaged throughout the book. They follow their love story and face dangerous situations due to the mafia world they occupy.

Halday hired St. Petersburg, Fla.-based company LAST Research and Editing to edit her first novel to provide the quality writing readers expect from Halday. “Louise has done a great job making this book the best it could be,” Halday said. “Now, it will delight mafia romance readers and thrill seekers throughout the United States.”

As a special for the week of Christmas, Halday plans to lower the price of the electronic version. She recommends buying it then for gifts or for readers themselves before the price is increased.

Paperback, hardback and electronic versions are available on Amazon. To get a bound copy, visit https://www.amazon.com/Shadowed-Desire-dangerous-irresistible-Brothers/dp/B0CQPNF7BW or https://www.amazon.com/Shadowed-Desire-dangerous-irrestible-love-ebook/dp/B0DPXPCHSY for the Kindle version.

Visit Alem Haliday’s author page

Media Contact
Company Name: LAST Research and Editing
Contact Person: Louise Harris
Email: Send Email
Phone: (480) 370-3945
Country: United States
Website: https://amazon.com/author/alemhalday